Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.71 |
| ▸ | RARG | P13631 | 1/20 | 0.59 |
| ▸ | RARA | P10276 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263090 | 0.89 | GCK (0.70) | GCKRARGRARARARB | |
| SCHEMBL1147056 | 0.89 | GCK (0.67) | GCKRARGRARARARB | |
| SCHEMBL3595846 | 0.89 | GCK (0.67) | GCKRARGRARARARB | |
| SCHEMBL1107704 | 0.88 | GCK (0.68) | GCKRARGRARARARB | |
| SCHEMBL1261335 | 0.87 | GCK (0.59) | GCKRARGRARARARB | |
| SCHEMBL1263418 | 0.86 | GCK (0.60) | GCKRARGRARARARB | |
| SCHEMBL1263158 | 0.85 | GCK (0.55) | GCKRARGRARARARB | |
| SCHEMBL17933978 | 0.84 | GCK (0.58) | GCKRARG | |
| SCHEMBL5653792 | 0.84 | GCK (1.00) | GCKRARGRARARARB | |
| SCHEMBL1107676 | 0.82 | GCK (0.54) | GCKRARGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7880012-B2 | e.g. 3-[2-(3-Isopropoxy-5-phenoxy-benzoylamino)-thiazol-5-yl-sulfanyl]-propionic acid methyl ester; metabolic disorder, blood glucose lowering, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, Polycystic Ovarian Syndrome, type I and type II diabetes, dyslipidemia, hyperlipidemia etc. | TRANSTECH PHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | VTVX HOLDINGS I LLC | 2010-12-30 | — | — | US | disclosed |
| EP-2019823-B1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, LLC | 2009-07-09 | — | — | US | disclosed |
| EP-2019823-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-2019824-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | GCK 1/4885RARG 3999/4885RARA 3803/4885 |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, HK2 | GCK 1/4885RARG 3945/4885RARA 3794/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | GCK 1/4885RARG 3999/4885RARA 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.